1. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R. et al., REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 10193: 121–130, 2019.
2. Riddle, M. New findings from the REWIND trial. Oral presentation S39.2. 55th Annual Meeting of EASD, Barcelona, 16.–20. 9. 2019. (online: www.easd.org) [cit 2. 11. 2020]
3. Gerstein, H. C. Effect of dulaglutide on serious health outcomes. Oral presentation S39.1. 55th Annual Meeting of EASD, Barcelona, 16.–20. 9. 2019. (online: www.easd.org) [cit 2. 11. 2020]
4. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). NCT01394952. ClinicalTrials.gov (online: www.clinicaltrials.gov) [cit 2. 11. 2020]
5. Scott, L. J. Dulaglutide: a review in type 2 diabetes. Drugs 80 2: 197–208, 2020.
6. Shaw, J. E., Botros, F. T., Malik, R. et al. Effect of dulaglutide on kidney function-related outcomes in type 2 diabetes: post hoc analysis from the REWIND trial. 356-OR. 80th Annual Scientific Sessions, Chicago, USA, 12.–16. 6. 2020.
7. Shaw, J., Botros, F. T., Malik, R. E. et al. Effect of dulaglutide on kidney function-related outcomes in type 2 diabetes: post hoc analysis from the REWIND trial. ePoster 585. 56th Annual Meeting, virtual meeting, 21.–25. 9. 2020. (online: www.easd.org) [cit 2. 11. 2020]
8. Colhoun, H., Malik, R., Botros, F. et al. Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR or albuminuria: a REWIND post hoc subroup analysis. ePoster 588. 56th Annual Meeting, virtual meeting, 21.–25. 9. 2020. (online: www.easd.org) [cit 2. 11. 2020]
9. REWIND – kardioprotektivita a renoprotektivita dulaglutidu u diabetiků 2. typu v kardiovaskulárním riziku. Kazuistiky v diabetologii 18, 4: 46–47, 2020.
10. Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19, 7: 582–590, 2020.
11. Nasreddine, Z. S., Phillips, N. A., Bédirian, V. et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53, 4: 6956–699, 2005.
12. Reban, J. Montrealský kognitivní test (MoCA): přínos k diagnostice predemencí. Česká geriatrická revue 4, 4: 224–229, 2006.
13. Rossetti, H. C., Lacritz, L. H., Cullum, C. M., Weiner, M. F. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 77, 13: 1272–1275, 2011.
14. Jaeger, J. Digit Symbol Substitution Test. J Clin Psychopharmacol 38, 5: 513–519, 2018.
15. Mohr, P., Bravermanová, A., Kratochvílová, Z. et al. Kognitivní poruchy u deprese. Čes a slov Psychiat 111, 6: 283–289, 2015.
16. Kopeček, M. Psychomotorické tempo, rychlost řeči a myšlení. Psychiat pro Praxi 8, 5: 213–215, 2007.